Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Meet with Modular Medical CEO, Jeb Besser Obesity is linked to 30% to 53% of new diabetes cases in the U.S. every year, per research in the Journal of the American Heart Association About half of all
Global Partners Reports Third-Quarter 2024 Financial Results
08:00am, Friday, 08'th Nov 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global” or the “Partnership”) today reported financial results for the third quarter ended September 30, 2024. CEO Commentary
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
09:15am, Thursday, 07'th Nov 2024
DehydraTECH™ for GLP-1 being optimized for global pharmaceutical use KELOWNA, BC / ACCESSWIRE / November 7, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"),
Modular Medical Announces Results from a Successful GLP-1 Proof of Concept Study
08:00am, Thursday, 07'th Nov 2024
-Study showed more potent weight loss and blood glucose control with the addition of a mealtime bolus of a rapid acting GLP-1 to basal delivery - Observed weight loss was 17% at 28 days, a 25% improve
Hims & Hers Health CFO talks GLP-1s, earnings
11:20am, Tuesday, 05'th Nov 2024
Hims & Hers Health (HIMS) shares jumped in extended trading after the company reported better than expected third quarter revenue and raised its outlook. The telehealth company swung to a profit, help
Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
10:30pm, Monday, 04'th Nov 2024
Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong buy rating despite FDA uncertainties. Shares rallied ~5% in after-hours trading
Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating'
06:28pm, Monday, 04'th Nov 2024
Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales forecast higher, as its efforts to offer more personalized care and more weight-l
13-week follow-up represents the longest data to-date demonstrating durable efficacy of RJVA-001 on weight and blood sugar in the diet-induced obesity (DIO) mouse model
Global Partners LP Completes Acquisition of East Providence Liquid Energy Terminal
11:45am, Friday, 01'st Nov 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE:GLP) (“Global” or the “Partnership”) announced today that it has successfully completed the acquisition of a liquid energy terminal in
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and
Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution?
10:45am, Sunday, 27'th Oct 2024
Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star.
Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings
12:11pm, Thursday, 24'th Oct 2024
Madrigal's Rezdiffra, the first FDA-approved drug for MASH, shows promise but faces competition from GLP-1 drugs and financial challenges in launching in Europe. Despite meeting Phase 3 endpoints and
Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
09:10am, Thursday, 24'th Oct 2024
DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups KELOWNA, BC / ACCESSWIRE / October 24, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:L
Global Partners LP to Host Third-Quarter 2024 Financial Results Conference Call on November 8, 2024
08:30am, Thursday, 24'th Oct 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (the “Partnership”) today announced that it will release its third-quarter 2024 financial results before the market opens on Friday,
Global Partners Declares Third-Quarter 2024 Cash Distribution of $0.7300 on Common Units
08:30am, Wednesday, 23'rd Oct 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (the “Partnership”) today announced that the Board of Directors of its general partner, Global GP LLC, has declared a cash distribut
